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Abstract
A sample size justification is a vital part of any trial design. However,
estimating the number of participants required to give a meaningful result
is not always straightforward. A number of components are required to
facilitate a suitable sample size calculation. In this paper, the steps for
conducting sample size calculations for non-inferiority and equivalence trials
are summarised. Practical advice and examples are provided that illustrate
how to carry out the calculations by hand and using the app SampSize.
1 Introduction
The introduction paper in this series highlighted the key components required
to estimate the sample size of a clinical trial [1]. This paper is a practical guide
for applying these steps to non-inferiority and equivalence, parallel group clinical
trials with a Normally distributed endpoint.
The paper begins by providing a brief explanation of noninferiority and equiv-
alence trials in context with their null and alternative hypotheses. Then the
formulae for sample size calculations are presented, highlighting the role of each
of the components.
Examples are used to demonstrate how this information is used in practice.
The examples are illustrated using the app SampSize [2] and also by hand to
emphasise the ease of calculating the sample size from the equations provided.
Details of how to obtain the app are provided in Table 1.
Table 1: How to obtain the app SampSize
The SampSize app is available on the Apple App
Store to download for free and can be used on
iPod Touch, iPad and iPhones. The app is also
available on the Android Market. It requires
Android version 2.3.3 and above.
For the calculations in this paper, an iPad is
used.
2 Components of a Sample Size
In the introduction to this series, the steps for a sample size calculation are
identified. Table 2 gives a summary of these points. An important step before
carrying out any sample size calculation is being able to complete this table.
Table 2: Summary of steps required for a sample size calculation
Step Summary
Objective Is the trial aiming to
show superiority, non-
inferiority or equiva-
lence?
Endpoint What endpoint will be
used to show the pri-
mary outcome? Nor-
mal, binary, ordinal or
time to event?
Error Type I error: How much
chance are you willing
to take of rejecting the
null when it is actually
true?
Type II error: How
much chance are you
willing to take of not re-
jecting the null when it
is actually false?
Non-inferiority or equivalence limit What is the minimum
clinically acceptable dif-
ference?
Population Variance What is the population
variability?
Other Do you need to account
for dropouts? How
many patients meet the
inclusion criteria?
3 Non-Inferiority Clinical Trials
In an investigation of a new intervention for a particular disease, a randomised
controlled trial can be conducted to investigate if the new treatment is superior
to a placebo control. However, once an existing therapy has been established,
it may no longer be ethical to undertake placebo controlled trials. Instead,
active-controlled trials can be conducted where a new treatment is compared
with an established treatment with the objective of demonstrating that the new
treatment is non-inferior. For certain trials, the objective therefore is not to
demonstrate that a new treatment is superior to placebo or equivalent to an es-
tablished treatment but rather to demonstrate that a given treatment is clinically
not inferior or no worse compared with another. The null (H0) and alternative
(H1) hypotheses for non-inferiority trials may take the form as follows:
H0: Treatment A is inferior in terms of the mean response µA−µB ≤ −dNI .
H1: Treatment A is non-inferior in terms of the mean response
µA − µB > −dNI .
The non-inferiority limit, dNI , is defined to be the difference that is clinically
acceptable for us to conclude that there is no difference between treatments.
Table 3 summarises how this limit might be selected.
Table 3: Summary of considerations in setting non-inferiority limits.
The setting of a non-inferiority limit is a controversial is-
sue. Regulatory guidelines exist to provide guidance on the
topic [3],[4]. The limit is defined as the largest difference
that is clinically acceptable, so that a difference bigger than
this would matter in practice [7]. This difference also can-
not be greater than the smallest effect size that the active
(control) drug would be reliably expected to have compared
with placebo in the setting of the planned trial [8].
The definition of an acceptable level of non-inferiority can be
made by making a retrospective comparison to placebo such
that if we can show that a new treatment is non-inferior to
standard treatment, we are indirectly demonstrating that
the new treatment is superior to the placebo [9]. In such
indirect comparisons, the following ABC needs to be con-
sidered [10][11]:
1. The Assay sensitivity of the active control in both the
placebo controlled trials and in the active-controlled non-
inferiority trial exists.
3. Bias is minimised through steps such as ensuring that
the patient population and the primary efficacy endpoint
are essentially the same for the placebo-controlled trial and
the active-controlled trial.
2. Constancy assumption of the effect of the common com-
parator. Such that for two trials in sequence (Trial 1 and
Trial 2), the control effect of Treatment B vs placebo in
Trial 1 is assumed to be the same as the control effect of
Treatment B vs placebo in Trial 2 had placebo been given.
Non-inferiority trials reduce to a simple one-sided hypothesis test. In prac-
tice, this is operationally the same as constructing a (1 − 2α)100% confidence
interval (CI) and concluding non-inferiority provided that the lower end of this
CI is greater than dNI .
Usually, non-inferiority trials (like equivalence trials discussed later) com-
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Figure 1: Formula for a non-inferiority parallel group trial.
pare the investigative therapy to an active control. Statistically, they could be
considered a special case of equivalence trials. However, they differ in one very
important aspect. For a non-inferiority trial, a mean difference a long way from
dNI , in a positive sense, is not a negative outcome for the study. While for an
equivalence trial, it would make demonstrating equivalence harder.
The distinction between non-inferiority and equivalence is important. Imag-
ine we were designing a role replacement study to assess the work of nurse
practitioners against doctors. For an equivalence assessment, we would wish
to show that nurse practitioners and doctors are the same with respect to an
appropriate clinical outcome, such that simultaneously we would wish to prove
that nurse practitioners are as good as doctors and doctors are as good as nurse
practitioners. However, with a non-inferiority trial, we would only wish to show
that nurse practitioners are as good as doctors. If they are better in other words
doctors are worse this would still be a positive outcome.
The sample size required for a non-inferiority clinical trial can be calculated
using the formula in Figure 1 [5],[6].
Table 4 gives common Normal deviates for different percentiles. For example,
for β = 0.1, we would have x = 0.1 and Z1−x = 1.282, while for α = 0.05, we
would have x = 0.025 and Z1−x = 1.96. These values are useful when calculating
a sample size by hand.
As for superiority trials, when the population variance will be assumed un-
known in the analysis of the trial, it is best to calculate the power under the
assumption of a non-central t distribution [5],[6]. This approach is used in the
Table 4: Normal deviates for common percentiles
x Z1−x
0.200 0.842
0.150 1.036
0.100 1.282
0.050 1.645
0.025 1.960
0.010 2.326
0.001 3.090
app SampSize
1− β = Probt
(
t1−α, nA(r + 1)− 2, nA(r + 1)− 2, τ
)
(1)
where τ is defined as
τ = |((µA − µB)− dNI)
√
rnA√
(r + 1)σ2
|
Probt(·) here is taken from the function in the package SAS (SAS Insti-
tute, Inc., Cary , NC, USA). To calculate the sample size, we can use Table
5, which gives calculated sample sizes for various standardised non-inferiority
limits (δNI = dNI/σ).
The percentage mean differences are given for the case where it is anticipated
that there may be a non-zero difference between treatments, that is, µA−µB 6= 0.
For example, if we had dNI = −10 (arbitrary scale) but we believed there may
be a small difference between treatments, such that µA − µB = 1, then the
percentage mean difference would be 1/10=10%, that is, the percentage of the
non-inferiority limit of the mean difference.
Note though the asymmetric effect on the sample size. This is because we
only need to show one bound of a 95% CI that has to exclude dNI . For the same
example, if we had dNI = −10 (scale arbitrary) but we believed that there may
be a small difference between treatments, such that µA−µB = 1, then when we
are designing the study, we are anticipating the mean difference to be 11 away
from the margin. Therefore, a smaller sample size is needed compared with the
assumption of µA − µB = 0 or µA − µB = 1.
For quick calculations (for 90% power and type I error of 2.5%), the following
result can be used [5][6]:
nA =
10.5σ2(r + 1)
((µA − µB)− dNI)2) (2)
In the case of r = 1 (2) resolves to:
nA =
21σ2
((µA − µB)− dNI)2) (3)
Table 6 discusses the rationale for setting the type I error in a non-inferiority
trial.
Table 5: Sample sizes (nA) for one arm of a parallel group non-inferiority study
with equal allocation for different standardised non-inferiority limits (δNI =
dNI/σ) and true mean differences (as a percentage of the non-inferiority limit)
for 90% power and type I error rate of 2.5% (from Equation (2)).
Percentage mean difference
δNI 25% 20% 15% 10% 5% 0% 5% 10% 15% 20% 25%
0.05 5381 5839 6358 6949 7626 8407 9316 10379 11636 13136 14945
0.10 1346 1461 1590 1738 1908 2103 2330 2596 2910 3285 3737
0.15 599 650 708 773 849 935 1036 1155 1294 1461 1662
0.20 338 366 399 436 478 527 584 650 729 822 935
0.25 217 235 256 279 306 338 374 417 467 527 599
0.30 151 164 178 194 213 235 260 290 325 366 417
0.35 111 121 131 143 157 173 192 213 239 270 306
0.40 86 93 101 110 121 133 147 164 183 207 235
0.45 68 74 80 87 96 105 116 130 145 164 186
0.50 55 60 65 71 78 86 95 105 118 133 151
0.55 46 50 54 59 64 71 78 87 98 110 125
0.60 39 42 46 50 54 60 66 74 82 93 105
0.65 33 36 39 43 47 51 57 63 70 79 90
0.70 29 31 34 37 40 44 49 54 61 68 78
0.75 25 27 30 32 35 39 43 48 53 60 68
0.80 23 24 26 29 31 34 38 42 47 53 60
0.85 20 22 23 26 28 31 34 37 42 47 53
0.90 18 20 21 23 25 27 30 34 37 42 48
0.95 16 18 19 21 23 25 27 30 34 38 43
1.00 15 16 17 19 21 23 25 27 31 34 39
Table 6: Rationale for setting a type I error for a non-inferiority trial.
The convention for non-inferiority trials is to set the type I
error rate at half of that used for a two-sided test used in a
superiority trial, i.e. α = 0.025, a type I error rate of 2.5%.
It is conventional for one-sided tests to have half the type I
error rate of two-sided tests [12].
It could be argued however that setting the type I error rate
for non-inferiority trials at half that for superiority trials is
consistent. This is because although in a superiority trial
we have a two-sided 5% significance level in practice, for
most trials, what we have is a one-sided investigation with
a 2.5% level of significance. The reason for this is that we
have an investigative therapy and a control therapy and it is
only the statistical superiority of the investigative therapy
that is of interest [9],[13]. It is logical therefore to formulate
superiority trials as a one-sided test - which is inevitable.
Operationally, statistical assessment of non-inferiority is the
same as constructing 95% CI and concluding non-inferiority
provided that the lower end of this CI is greater than dNI .
While for a superiority trial, statistical assessment of supe-
riority is the same as constructing 95% CI and concluding
superiority provided that the lower end of this CI is greater
than 0.
Through the rest of the sections on equivalence and non-
inferiority trials, the assumption will be that α = 0.025 and
that 95% CIs will be used in the final statistical analysis.
Figure 2: Screen shot of SampSize app for non-inferiority worked example with
standardised differences.
3.1 Worked Example
A trial is to be undertaken to investigate the effect of a new pain treatment
of rheumatoid arthritis. The trial design being considered is a non-inferiority
study. The objective is to show that the new treatment is as good as standard
therapy. The primary endpoint will be pain measured on a visual analogue
scale. The non-inferiority limit is 2.5mm. The standard deviation is anticipated
to be 10mm; assuming a one-sided type I error rate of 2.5% and 90% power.
The investigator wishes to estimate the sample size per arm. The true mean
difference between the treatments is thought to be zero.
After identifying the key points summarised in Table 7, it is possible to plug
the values into the formula in Figure 1. This gives:
nA =
(1 + 1)(Z1−0.1 + Z1−0.025)
2(102)
1× 2.52 (4)
Using the percentiles from Table 4, the sample size is calculated to be 336
for each group.
With a non-inferiority limit of 2.5 and a standard deviation of 10 from Table
V, the sample size is estimated to be 338 patients per arm.
If we believed that there has to be a small difference of 0.5 between treat-
ments, which equates to (0.5/2.5) 20% of the non-inferiority limit, then the
sample size could be reduced to 235 patients per arm. The sample size is re-
duced as the assumption is that there is a small difference, in favour of the
investigative treatment, and so, under this assumption, it should be easier to
show non-inferiority.
Repeating the calculation with the SampSize app select Non-Inferiority then
Parallel Group, Normal and Calculated Sample Size. Example entries and output
using standardised entries (standard deviation of 1 and non-inferiority limit of
2.5/10=0.25) are given in Figure 2 using the assumption of a zero difference.
Example entries and output using the original scale of the non-inferiority
limits and standard deviation are shown in Figure 3 using the assumption of a
0.5 difference between treatments. Note that a non-inferiority limit of 2.5 and
difference of -0.5 equates to the same calculation as a non-inferiority limit of -2.5
and a difference of 0.5.
The SampSize app also gives the sample size as 338 and 235 patients per arm
for a difference of 0 and 0.5, respectively, the same as the results from Table 5.
3.2 Superiority Trials Revisited
In a superiority trial, the objective is to determine whether there is evidence of
a statistical difference in the comparator of interest between the regimens with
reference to the null hypothesis that the regimens are the same.
Something we glossed over in the earlier papers was that for superiority
trials, the alternative hypothesis is such that the treatments are not equal or not
equivocal [1],[14], not that one treatment is superior [12]. Formally, a superiority
trial should be formulated as follows:
Figure 3: Screen shot of SampSize app for non-inferiority worked example on
original scale.
Table 7: Key components required for sample size for a non-inferiority trial.
Step Summary
Objective Non-inferiority: H0 :
µA−µB ≤ −dNI vs H1 :
µA − µB > −dNI
Endpoint Improvement in visual
analogue pain
Error Type I error α = 0.05
Type II error β = 0.1,
power 1− β = 0.9
Non-Inferiority Limit dNI = 2.5mm
Population Variance σ = 10mm
Other r = 1
H0: There is no difference between treatments in terms of the mean response
µA = µB.
H1: A given treatment is superior in terms of the mean response µA > µB.
where in the definition of the null and alternative hypotheses, µA and µB refer
to the mean response on regimens A and B, respectively.
In our discussion, we highlight how, in effect, non-inferiority studies are one-
sided tests. The same could be said for superiority trials. However, in our
earlier paper, we have used the convention of a two-sided test for superiority. It
could be argued this is not strictly correct but it is consistent with International
Conference on Harmonisation (ICH) E9 guidelines [12].
3.3 As Good As or Better Trials
For some clinical trials, the objective is to demonstrate that either a given treat-
ment is clinically non-inferior or that it is clinically superior when compared
with the control, that is, the treatment is as good as or better than the control
[5][6][15]. In as good as or better trials, two null and alternative hypotheses are
investigated. First, the non-inferiority null and alternative hypotheses:
H0: A given treatment is inferior with respect to the mean response.
H1: The given treatment is non-inferior with respect to the mean response.
If this null hypothesis is rejected, then a second, superiority null hypothesis
can be investigated:
H0: The two treatments have equal effect with respect to the mean response.
H1: The two treatments are different with respect to the mean response.
Operationally, these null hypotheses are investigated through the construction
of a 95% CI to investigate where the lower (or upper as appropriate) bound
lies. If it excludes the non-inferiority limit, then a conclusion of non-inferiority
can be made, while if it excludes zero, a conclusion of superiority can be made.
As good as or better trials therefore combine the null hypotheses of superiority
and non-inferiority trials into one closed testing procedure while maintaining the
overall type I error rate by undertaking a non-inferiority test followed by a test
for superiority.
The method used depends on the primary objective of the trial. For example,
if the primary objective is to investigate non-inferiority, under the assumption
of a small difference between treatments, then the sample size can be calculated
for this objective. A calculation can then be made as to what power the study
has with the calculated non-inferiority sample size for the superiority objective.
Note that in these calculations consideration would need to be made as to
the primary analysis population. For a superiority trial, the primary data set
may be that is based on an intention to treat (ITT) data set; for a non-inferiority
trial, the primary data set may be both the per protocol and the ITT data set
[5].
4 Equivalence Trials
In certain cases, the objective of a study is not to demonstrate superiority of
one treatment over another but to show that two treatments have no clinically
meaningful difference, that is, they are clinically equivalent. The null (H0) and
alternative (H1) hypotheses for such equivalence trials take the form as follows:
H0: There is a clinically meaningful difference between treatments in terms
of the mean response: µA − µB ≤ −dE and µA − µB ≥ −dE .
H1: There is no clinically meaningful difference between treatments in terms
of the mean response −dE < µA − µB < dE .
The equivalence limit dE , equates to the largest difference clinically accept-
able for us to conclude no difference between treatments.
These hypotheses are an example of an intersection-union test, in which the
null hypothesis is expressed as a union and the alternative as an intersection [5].
Therefore, to conclude equivalence, we need to reject each component of the null
hypothesis.
An approach with equivalence trials is to test each component of the null
hypothesis called the two one-sided test (TOST) procedure. In practice, this
is operationally the same as constructing a (1 − 2α)100% CI and concluding
equivalence if the CI falls completely within the interval (−dE ,+dE).
For example, if dE is set to be 10 (arbitrary scale), and after conducting a
trial, a 95% CI for the difference between treatments is found to be (-3, 7). This
interval is wholly contained within (-10, 10) so it is possible to conclude that the
two treatments are equivalent.
Note that although not covered in this paper, bioequivalence trials are sim-
ilar, in an operational sense, to the equivalence trials in terms of the null and
alternative hypotheses [5]. The main difference statistically is that the type I er-
ror is 5% and 90% CIs are used. There are of course bigger differences clinically
in their objectives. The rationale for setting the type I error in an equivalence
trials is discussed in Table 8.
For equivalence trials, the sample size cannot be derived directly for the
general case where the expected true mean difference is non-zero. Instead, the
power (and type II error rate) needs to be calculated for a given sample size
[5],[6].
1− β = Φ
(√
((µA − µB)− dE)2rnA
(r + 1)σ2
− Z1−α
)
(5)
+ Φ
(√
((µA − µB) + dE)2rnA
(r + 1)σ2
− Z1−α − 1
)
The sample size is then estimated by iterating until the required power is
reached. As with non-inferiority and superiority trials, it is best to use a non-
central t distribution to calculate the type II error and power. From a non-central
t distribution, the power can be calculated using the following formula [5],[6]
1− β = Probt(− t1−α,nA(r+1)−2, nA(r + 1)− 2, τ2) (6)
− Probt(t1−α,nA(r+1)−2, nA(r + 1)− 2, τ1)
where τ1 and τ2 are non-centrality parameters defined as follows
τ1 = |
((µA − µB) + dE)√rnA√
(r + 1)σ2
|
τ2 = |
((µA − µB)− dE)√rnA√
(r + 1)σ2
|
Result (6) is used to estimate the sample sizes in Table 9. For the special
case of no treatment difference, a direct estimate of the sample size is given in
Figure 4.
While under the assumption of a non-central t distribution, the power can
be derived from
1− β = 2Probt(− t1−α,nA(r+1)−2, nA(r + 1)− 2, τ − 1) (7)
where τ is defined as
τ =
−√nArdE√
(r + 1)σ2
. (8)
For quick calculations of no treatment difference (for 90% power and type I
error rate of 2.5%), the following result can be used
nA =
13σ2(r + 1)
d2Er
. (9)
or for r = 1
nA =
26σ2
d2E
. (10)
Table 8: Rationale for setting a type I error for an equivalence trial.
Strictly speaking, when undertaking two simul-
taneous one-sided tests, setting α = 0.05 will
maintain an overall type I error rate of 5%. How-
ever, convention for equivalence trials like for
non-inferiority trials described earlier is to set
the type I error rate at half of that which would
be employed for a two-sided test used in a supe-
riority trial, i.e. α = 0.025, a type I error rate
of 2.5%.
This is effectively an investigation of two sepa-
rate null and alternative hypotheses of the form:
H0 : µA − µB ≤ −dE
H1 : µA − µB > −dE
and
H0 : µA − µB ≥ dE
H1 : µA − µB < dE
Each of the null and alternative hypotheses look
like a non-inferiority test. If we can reject the
null hypothesis for each test so we can declare
Treatment A to be non-inferior to Treatment B
and Treatment B to be non-inferior to A, we can
accept the alternative hypothesis of equivalence.
In this context, the setting of the type I error at
2.5% is consistent with non-inferiority trials.
Table 9: Sample sizes (nA) for one arm of a parallel group equivalence study with
equal allocation for different standardised equivalence limits(as a percentage of
the equivalence limit) 90% power and type I error rate of 2.5% (from Equation
(6)).
Percentage mean difference
δR 0% 10% 15% 20 25%
0.05 10397 11042 11915 13218 14960
0.10 2600 2762 2980 3306 3741
0.15 1157 1228 1325 1470 1664
0.20 651 691 746 827 936
0.25 417 443 478 530 600
0.30 290 308 332 369 417
0.35 214 227 245 271 307
0.40 164 174 188 208 235
0.45 130 138 149 165 186
0.50 105 112 121 134 151
0.55 87 93 100 111 125
0.60 74 78 84 93 105
0.65 63 67 72 80 90
0.70 55 58 62 69 78
0.75 48 51 54 60 68
0.80 42 45 48 53 60
0.85 37 40 43 47 53
0.90 34 36 38 42 48
0.95 30 32 34 38 43
1.00 27 29 31 35 39
Type II error (Ⱦ) Type I error (Ƚ) 
Equivalence Limit (dE) Allocation ratio (r) 
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Figure 4: Formula for an equivalence parallel group trial.
4.1 Worked Example
Consider again the trial to investigate the effect of a new pain treatment of
rheumatoid arthritis. The objective now is to show that the new treatment
is equivalent to a standard therapy. The primary endpoint pain is measured
on a visual analogue scale. The largest clinically acceptable effect for which
equivalence can be declared is a mean difference of 2.5 mm. The standard
deviation is anticipated to be 10 mm; assuming a one-sided type I error of 2.5%
and 90% power. The investigator wishes to estimate the sample size per arm.
The true mean difference between the treatments is thought to be zero. After
identifying these key points summarised in Table 10, it is possible to plug the
values into the formula in Figure 4. This gives
nA =
(1 + 1)(Z1−0.1/2 + Z1−0.025)
2
1× 2.52 . (11)
Using the common percentiles from Table IV, the sample size is calculated to be
416 for each group. With an equivalence limit of 2.5 and a standard deviation
of 10 from Table 9, the sample size is estimated to be 417 patients per arm.
If we believed there to be is a small difference of 0.5 between treatments,
which equates to 20% of the equivalence limit, then the sample size would need
to be increased to 530 patients per arm. The sample size is increased as it is
harder to show equivalence with a small difference between treatments than with
no difference between treatments.
Table 10: Key components required for sample size for an equivalence trial.
Step Summary
Objective Superiority: H0 : µA − µB ≤ dE or
H0 : µA−µB ≥ +dE vs H1 : −dE <
µA − µB > dE
Endpoint Improvement in visual analogue
pain
Error Type I error α = 0.025
Type II error β = 0.1, power 1−β =
0.9
Equivalence limit dE = 2.5mm
Population standard deviation σ = 10mm
Other r = 1
Repeating the calculation with the SampSize app select Equivalence then
Parallel Group, Normal and Sample Size. Example entries and output for the
calculation of an equivalence limit of 2.5 and a mean difference of 0.5 are given
in Figure 5.
The SampSize app also gives the sample size as 417 and 530 patients per arm
for a difference of 0 and 0.5, respectively.
5 Summary
The paper described sample size calculations for trials with a Normally dis-
tributed primary endpoint and highlighted how the different non-inferiority and
equivalence objectives can impact on calculations. Statistical tables and the app,
SampSize, have been used to demonstrate a number of examples of sample size
calculations.
While the emphasis of this paper is on trials with a Normally distributed
primary endpoint, the principles described can be generally applied to different
designs and distributional forms [5],[6].
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